Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17198
Corporate User License Price USD 750
Corporate User License Price INR 51593
Site License Price USD 500
Site License Price INR 34395
Request a Quote

Report Title

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, critical and supportive care. Norgine offers drugs in the form of capsules, solutions, tablets, oral powder and medical device. The company also provides clinical supply services to organizations conducting clinical trials. It operates in the UK, France, Belgium, Germany and the Netherlands, among others. Norgine is headquartered in Amsterdam, the Netherlands.

Norgine BV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Norgine BV, Medical Devices Deals, 2012 to YTD 2018 12

Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Norgine BV, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 15

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 16

Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 17

Merus Labs Acquires Sintrom from Novartis 18

Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 19

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 20

Partnerships 21

Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 21

Norgine Forms Joint Venture With SpePharm Holding 22

Merus Labs Enters into Agreement with Vansen Pharma 23

Licensing Agreements 24

Norgine Enters into Licensing Agreement with Shield Therapeutics 24

Navidea Enters into License Agreement with Norgine for Lymphoseek 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 28

Valeant Pharma Enters into Licensing Agreement with Norgine 29

Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 30

Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 31

Equity Offering 32

Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 32

Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 34

Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 35

Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 36

Merus Labs Raises USD28.7 Million in Public Offering of Shares 37

Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For USD 20.7 Million 38

Merus Labs Completes Private Placement Of Shares For USD 4.4 Million 39

Merus Labs Announces Public Offering Of Common Shares For USD 10.1 Million 40

Asset Transactions 41

Searchlight Pharma Acquires Canadian Assets from Norgine 41

Norgine Divests its MENA Operations and Product Rights to Acino 42

Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 43

Norgine to Sell UK Rights for Somnite and Camcolit 44

Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to USD 3.4 Million 45

Acquisition 47

Norgine Acquires Merus Labs International 47

Norgine BV-Key Competitors 49

Norgine BV-Key Employees 50

Norgine BV-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Joint Venture 53

Recent Developments 54

Strategy And Business Planning 54

Jul 20, 2018: Norgine opens its new German offices in Wettenberg 54

Jan 24, 2018: Norgine Opens New Headquarters in Amsterdam, Netherlands 55

Financial Announcements 56

Sep 12, 2018: Norgine releases H1 2018 results 56

Government and Public Interest 57

Mar 27, 2018: Norgine Is Calling The NHS To Remove Constipation From The List Of Restricted Conditions In Proposed CCGs Guidance-Constipation Is A Very Serious Condition 57

Product News 59

Oct 31, 2017: Norgine Launches PLENVU (NER1006) in the United Kingdom 59

Apr 21, 2018: New Data Show That High Quality Cleansing Improves Lesion Detection During Colonoscopy Compared to Adequate Cleansing 60

Other Significant Developments 61

Feb 26, 2018: Norgine's Performance in 2017 and Priorities for 2018 61

Feb 16, 2017: Norgine Rejoins The UK Pharmaceutical Trade Body ABPI 62

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Norgine BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Norgine BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Norgine BV, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

Norgine BV, Pharmaceuticals & Healthcare, Key Facts 2

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Norgine BV, Deals By Therapy Area, 2012 to YTD 2018 10

Norgine BV, Medical Devices Deals, 2012 to YTD 2018 12

Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 15

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 16

Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 17

Merus Labs Acquires Sintrom from Novartis 18

Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 19

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 20

Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 21

Norgine Forms Joint Venture With SpePharm Holding 22

Merus Labs Enters into Agreement with Vansen Pharma 23

Norgine Enters into Licensing Agreement with Shield Therapeutics 24

Navidea Enters into License Agreement with Norgine for Lymphoseek 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 28

Valeant Pharma Enters into Licensing Agreement with Norgine 29

Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 30

Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 31

Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 32

Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 34

Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 35

Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 36

Merus Labs Raises USD28.7 Million in Public Offering of Shares 37

Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For USD 20.7 Million 38

Merus Labs Completes Private Placement Of Shares For USD 4.4 Million 39

Merus Labs Announces Public Offering Of Common Shares For USD 10.1 Million 40

Searchlight Pharma Acquires Canadian Assets from Norgine 41

Norgine Divests its MENA Operations and Product Rights to Acino 42

Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 43

Norgine to Sell UK Rights for Somnite and Camcolit 44

Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to USD 3.4 Million 45

Norgine Acquires Merus Labs International 47

Norgine BV, Key Competitors 49

Norgine BV, Key Employees 50

Norgine BV, Other Locations 51

Norgine BV, Subsidiaries 51

Norgine BV, Joint Venture 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Norgine BV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person